{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T02:01:22Z","timestamp":1791597682472,"version":"4.3.4"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2018,3,15]],"date-time":"2018-03-15T00:00:00Z","timestamp":1521072000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100009045","name":"Uniwersytet Jagiello\u0144ski Collegium Medicum","doi-asserted-by":"publisher","award":["K\/DSC\/003114"],"award-info":[{"award-number":["K\/DSC\/003114"]}],"id":[{"id":"10.13039\/100009045","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1007\/s10067-018-4061-y","type":"journal-article","created":{"date-parts":[[2018,4,3]],"date-time":"2018-04-03T21:39:51Z","timestamp":1522791591000},"page":"1597-1604","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Age determines response to anti-TNF\u03b1 treatment in patients with ankylosing spondylitis and is related to TNF\u03b1-producing CD8 cells"],"prefix":"10.1007","volume":"37","author":[{"given":"Agata","family":"Schramm-Luc","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jolanta","family":"Schramm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mateusz","family":"Siedli\u0144ski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomasz J.","family":"Guzik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bogdan","family":"Batko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,3,15]]},"reference":[{"issue":"6","key":"4061_CR1","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1136\/annrheumdis-2016-210770","volume":"76","author":"D Heijde van der","year":"2017","unstructured":"van der Heijde D, Ramiro S, Landewe R, Baraliakos X, Van den Bosch F, Sepriano A, Regel A, Ciurea A, Dagfinrud H, Dougados M, van Gaalen F, Geher P, van der Horst-Bruinsma I, Inman RD, Jongkees M, Kiltz U, Kvien TK, Machado PM, Marzo-Ortega H, Molto A, Navarro-Compan V, Ozgocmen S, Pimentel-Santos FM, Reveille J, Rudwaleit M, Sieper J, Sampaio-Barros P, Wiek D, Braun J (2017) 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis 76(6):978\u2013991. \n                    https:\/\/doi.org\/10.1136\/annrheumdis-2016-210770","journal-title":"Ann Rheum Dis"},{"key":"4061_CR2","doi-asserted-by":"publisher","unstructured":"Chen JM, Veras MMS, Liu C, Lin JF (2013) Methotrexate for ankylosing spondylitis. Cochrane Db Syst Rev (2):Cd004524. doi:\n                    https:\/\/doi.org\/10.1002\/14651858.Cd004524.Pub4","DOI":"10.1002\/14651858.Cd004524.Pub4"},{"issue":"4","key":"4061_CR3","doi-asserted-by":"publisher","first-page":"801","DOI":"10.3899\/jrheum.081048","volume":"36","author":"M Rudwaleit","year":"2009","unstructured":"Rudwaleit M, Claudepierre P, Wordsworth P, Cortina EL, Sieper J, Kron M, Carcereri-de-Prati R, Kupper H, Kary S (2009) Effectiveness, safety, and predictors of good clinical response in 1250 patients treated with adalimumab for active ankylosing spondylitis. J Rheumatol 36(4):801\u2013808. \n                    https:\/\/doi.org\/10.3899\/jrheum.081048","journal-title":"J Rheumatol"},{"issue":"3","key":"4061_CR4","doi-asserted-by":"publisher","first-page":"R94","DOI":"10.1186\/ar3369","volume":"13","author":"S Arends","year":"2011","unstructured":"Arends S, Brouwer E, van der Veer E, Groen H, Leijsma MK, Houtman PM, Jansen TLTA, Kallenberg CGM, Spoorenberg A (2011) Baseline predictors of response and discontinuation of tumor necrosis factor-alpha blocking therapy in ankylosing spondylitis: a prospective longitudinal observational cohort study. Arthritis Res Ther 13(3):R94. \n                    https:\/\/doi.org\/10.1186\/Ar3369","journal-title":"Arthritis Res Ther"},{"issue":"6","key":"4061_CR5","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1136\/ard.2003.016386","volume":"63","author":"M Rudwaleit","year":"2004","unstructured":"Rudwaleit M, Listing J, Brandt J, Braun J, Sieper J (2004) Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis. Ann Rheum Dis 63(6):665\u2013670. \n                    https:\/\/doi.org\/10.1136\/ard.2003.016386","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"4061_CR6","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1002\/art.1780270401","volume":"27","author":"S Vanderlinden","year":"1984","unstructured":"Vanderlinden S, Valkenburg HA, Cats A (1984) Evaluation of diagnostic-criteria for ankylosing-spondylitis\u2014a proposal for modification of the New York criteria. Arthritis Rheum 27(4):361\u2013368","journal-title":"Arthritis Rheum"},{"issue":"12","key":"4061_CR7","first-page":"2286","volume":"21","author":"S Garrett","year":"1994","unstructured":"Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A (1994) A new approach to defining disease status in ankylosing-spondylitis\u2014the Bath Ankylosing-Spondylitis Disease-Activity Index. J Rheumatol 21(12):2286\u20132291","journal-title":"J Rheumatol"},{"issue":"12","key":"4061_CR8","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1136\/ard.2008.100826","volume":"68","author":"D Heijde van der","year":"2009","unstructured":"van der Heijde D, Lie E, Kvien TK, Sieper J, Van den Bosch F, Listing J, Braun J, Landewe R, Soc ASI (2009) ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis. Ann Rheum Dis 68(12):1811\u20131818. \n                    https:\/\/doi.org\/10.1136\/ard.2008.100826","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"4061_CR9","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/j.exger.2004.01.009","volume":"39","author":"KS Krabbe","year":"2004","unstructured":"Krabbe KS, Pedersen M, Bruunsgaard H (2004) Inflammatory mediators in the elderly. Exp Gerontol 39(5):687\u2013699. \n                    https:\/\/doi.org\/10.1016\/j.exger.2004.01.009","journal-title":"Exp Gerontol"},{"key":"4061_CR10","doi-asserted-by":"publisher","first-page":"S422","DOI":"10.1513\/AnnalsATS.201602-095AW","volume":"13","author":"CM Weyand","year":"2016","unstructured":"Weyand CM, Goronzy JJ (2016) Aging of the immune system mechanisms and therapeutic targets. Ann Am Thorac Soc 13:S422\u2013S428. \n                    https:\/\/doi.org\/10.1513\/AnnalsATS.201602-095AW","journal-title":"Ann Am Thorac Soc"},{"issue":"4","key":"4061_CR11","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1111\/sji.12413","volume":"83","author":"R Valiathan","year":"2016","unstructured":"Valiathan R, Ashman M, Asthana D (2016) Effects of ageing on the immune system: infants to elderly. Scand J Immunol 83(4):255\u2013266. \n                    https:\/\/doi.org\/10.1111\/sji.12413","journal-title":"Scand J Immunol"},{"issue":"9","key":"4061_CR12","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1016\/S0531-5565(03)00160-8","volume":"38","author":"F Zanni","year":"2003","unstructured":"Zanni F, Vescovini R, Biasini C, Fagnoni F, Zanlari L, Telera A, Di Pede P, Passeri G, Pedrazzoni M, Passeri M, Franceschi C, Sansoni P (2003) Marked increase with age of type 1 cytokines within memory and effector\/cytotoxic CD8(+) T cells in humans: a contribution to understand the relationship between inflammation and immunosenescence. Exp Gerontol 38(9):981\u2013987. \n                    https:\/\/doi.org\/10.1016\/S0531-5565(03)00160-8","journal-title":"Exp Gerontol"},{"issue":"5","key":"4061_CR13","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1136\/ard.2005.042085","volume":"65","author":"C Duftner","year":"2006","unstructured":"Duftner C, Dejaco C, Kullich W, Klauser A, Goldberger C, Falkenbach A, Schirmer M (2006) Preferential type 1 chemokine receptors and cytokine production of CDs28(\u2212) T cells in ankylosing spondylitis. Ann Rheum Dis 65(5):647\u2013653. \n                    https:\/\/doi.org\/10.1136\/ard.2005.042085","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"4061_CR14","doi-asserted-by":"publisher","first-page":"3231","DOI":"10.4049\/jimmunol.167.6.3231","volume":"167","author":"E Bryl","year":"2001","unstructured":"Bryl E, Vallejo AN, Weyand CM, Goronzy JJ (2001) Down-regulation of CD28 expression by TNF-alpha. J Immunol 167(6):3231\u20133238","journal-title":"J Immunol"},{"issue":"14","key":"4061_CR15","doi-asserted-by":"publisher","first-page":"8119","DOI":"10.1074\/jbc.273.14.8119","volume":"273","author":"AN Vallejo","year":"1998","unstructured":"Vallejo AN, Nestel AR, Schirmer M, Weyand CM, Goronzy JJ (1998) Aging-related deficiency of CD28 expression in CD4+ T cells is associated with the loss of gene-specific nuclear factor binding activity. J Biol Chem 273(14):8119\u20138129. \n                    https:\/\/doi.org\/10.1074\/jbc.273.14.8119","journal-title":"J Biol Chem"},{"issue":"5","key":"4061_CR16","doi-asserted-by":"publisher","first-page":"R292","DOI":"10.1186\/ar793","volume":"5","author":"C Duftner","year":"2003","unstructured":"Duftner C, Goldberger C, Falkenbach A, Wurzner R, Falkensammer B, Pfeiffer KP, Maerker-Hermann E, Schirmer M (2003) Prevalence, clinical relevance and characterization of circulating cytotoxic CD4(+)CD28(\u2212) T cells in ankylosing spondylitis. Arthritis Res Ther 5(5):R292\u2013R300. \n                    https:\/\/doi.org\/10.1186\/ar793","journal-title":"Arthritis Res Ther"},{"issue":"10","key":"4061_CR17","doi-asserted-by":"publisher","first-page":"e7556","DOI":"10.1371\/journal.pone.0007556","volume":"4","author":"A Julia","year":"2009","unstructured":"Julia A, Erra A, Palacio C, Tomas C, Sans X, Barcelo P, Marsal S (2009) An eight-gene blood expression profile predicts the response to infliximab in rheumatoid arthritis. PLoS One 4(10):e7556. \n                    https:\/\/doi.org\/10.1371\/journal.pone.0007556","journal-title":"PLoS One"},{"issue":"6","key":"4061_CR18","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.jbspin.2015.03.003","volume":"82","author":"HT Liao","year":"2015","unstructured":"Liao HT, Lin YF, Tsai CY, Chou CT (2015) Regulatory T cells in ankylosing spondylitis and the response after adalimumab treatment. Joint Bone Spine 82(6):423\u2013427. \n                    https:\/\/doi.org\/10.1016\/j.jbspin.2015.03.003","journal-title":"Joint Bone Spine"},{"key":"4061_CR19","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1196\/annals.1361.095","volume":"1051","author":"E Toubi","year":"2005","unstructured":"Toubi E, Kessel A, Mahmudov Z, Hallas K, Rozenbaum M, Rosner AI (2005) Increased spontaneous apoptosis of CD4(+)CD25(+) T cells in patients with active rheumatoid arthritis is reduced by infliximab. Ann N Y Acad Sci 1051:506\u2013514. \n                    https:\/\/doi.org\/10.1196\/annals.1361.095","journal-title":"Ann N Y Acad Sci"},{"issue":"2","key":"4061_CR20","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1111\/j.1365-2249.2012.04600.x","volume":"169","author":"J Grundstrom","year":"2012","unstructured":"Grundstrom J, Linton L, Thunberg S, Forsslund H, Janczewska I, Befrits R, van Hage M, Gafvelin G, Eberhardson M (2012) Altered immunoregulatory profile during anti-tumour necrosis factor treatment of patients with inflammatory bowel disease. Clin Exp Immunol 169(2):137\u2013147. \n                    https:\/\/doi.org\/10.1111\/j.1365-2249.2012.04600.x","journal-title":"Clin Exp Immunol"},{"issue":"1","key":"4061_CR21","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/s10875-012-9774-0","volume":"33","author":"XY Li","year":"2013","unstructured":"Li XY, Chen LN, Wu ZB, Han Q, Li Q, Ping Z (2013) Levels of circulating Th17 cells and regulatory T cells in ankylosing spondylitis patients with an inadequate response to anti-TNF-alpha therapy. J Clin Immunol 33(1):151\u2013161. \n                    https:\/\/doi.org\/10.1007\/s10875-012-9774-0","journal-title":"J Clin Immunol"},{"issue":"10","key":"4061_CR22","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1093\/rheumatology\/ket249","volume":"52","author":"A Spadaro","year":"2013","unstructured":"Spadaro A, Lubrano E, Marchesoni A, D'Angelo S, Ramonda R, Addimanda O, Perrotta FM, Olivieri I, Punzi L, Salvarani C (2013) Remission in ankylosing spondylitis treated with anti-TNF-alpha drugs: a national multicentre study. Rheumatology 52(10):1914\u20131919. \n                    https:\/\/doi.org\/10.1093\/rheumatology\/ket249","journal-title":"Rheumatology"},{"issue":"5","key":"4061_CR23","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1093\/rheumatology\/ket433","volume":"53","author":"E Gremese","year":"2014","unstructured":"Gremese E, Bernardi S, Bonazza S, Nowik M, Peluso G, Massara A, Tolusso B, Messuti L, Miceli MC, Zoli A, Trotta F, Govoni M, Ferraccioli G (2014) Body weight, gender and response to TNF-alpha blockers in axial spondyloarthritis. Rheumatology 53(5):875\u2013881. \n                    https:\/\/doi.org\/10.1093\/rheumatology\/ket433","journal-title":"Rheumatology"},{"key":"4061_CR24","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1186\/s13075-017-1372-3","volume":"19","author":"R Micheroli","year":"2017","unstructured":"Micheroli R, Hebeisen M, Wildi LM, Exer P, Tamborrini G, Bernhard J, Moller B, Zufferey P, Nissen MJ, Scherer A, Ciurea A, Qua RSC (2017) Impact of obesity on the response to tumor necrosis factor inhibitors in axial spondyloarthritis. Arthritis Res Ther 19:164. \n                    https:\/\/doi.org\/10.1186\/S13075-017-1372-3","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"4061_CR25","doi-asserted-by":"publisher","first-page":"41","DOI":"10.3109\/03009742.2012.715186","volume":"42","author":"F Iannone","year":"2013","unstructured":"Iannone F, Fanizzi R, Scioscia C, Anelli MG, Lapadula G (2013) Body mass does not affect the remission of psoriatic arthritis patients on anti-TNF-alpha therapy. Scand J Rheumatol 42(1):41\u201344. \n                    https:\/\/doi.org\/10.3109\/03009742.2012.715186","journal-title":"Scand J Rheumatol"},{"key":"4061_CR26","doi-asserted-by":"publisher","first-page":"32202","DOI":"10.1038\/srep32202","volume":"6","author":"J Liu","year":"2016","unstructured":"Liu J, Dong Z, Zhu Q, He DY, Ma YY, Du AP, He F, Zhao DB, Xu X, Zhang H, Jin L, Wang JC (2016) TNF-alpha promoter polymorphisms predict the response to etanercept more powerfully than that to infliximab\/adalimumab in spondyloarthritis. Sci Rep-Uk 6:32202. \n                    https:\/\/doi.org\/10.1038\/Srep32202","journal-title":"Sci Rep-Uk"},{"issue":"9","key":"4061_CR27","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1136\/ard.2007.073098","volume":"67","author":"M Rudwaleit","year":"2008","unstructured":"Rudwaleit M, Schwarzlose S, Hilgert ES, Listing J, Braun J, Sieper J (2008) MRI in predicting a major clinical response to anti-tumour necrosis factor treatment in ankylosing spondylitis. Ann Rheum Dis 67(9):1276\u20131281. \n                    https:\/\/doi.org\/10.1136\/ard.2007.073098","journal-title":"Ann Rheum Dis"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10067-018-4061-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-018-4061-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-018-4061-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,3,14]],"date-time":"2019-03-14T20:45:52Z","timestamp":1552596352000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10067-018-4061-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,15]]},"references-count":27,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["4061"],"URL":"https:\/\/doi.org\/10.1007\/s10067-018-4061-y","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,15]]},"assertion":[{"value":"14 November 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"This study is in accordance with ethical principles of the Helsinki declaration. The investigation protocol was approved by the Bioethics Committee of the Regional Chamber of Physicians in Cracow, Poland\u2014investigation number 77\/KBL\/OIL\/2013. Prior to enrolment, written consent was obtained from all patients.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"None.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}